Fluorescence In-Situ Hybridization (FISH) Report: 111111

Technology specifies what assay was performed

Date Reported: September 18, 2025
Technology: Fluorescence In-Situ Hybridization (FISH)
Cell Line: Sample Report
Cell Line Sex: Female
Submitted Passage #: 23
Reason for Testing: LOT_RELEASE
Date of Sample: 9/16/2025
Harvest Date: 9/16/2025

Harvest Date has been added

Specimen: Human ESC
Investigator: WiCell Stem Cell Bank, WiCell
Process Description #: WIC001

Results:

Probe	# of cells with 2G1R pattern	# of cells with 2G2R pattern	# of cells with 2G3R pattern	# of cells with 1G3R pattern	# of cells with 1G2R pattern
20p11 (G) / BCL2L1 (R)	2 / 200 (1.0%)	148 / 200 (74.0%)	45 / 200 (22.5%)	1 / 200 (0.5%)	4 / 200 (2.0%)
Cutoff	4.0%	N/A	6.0%	3.0%	4.0%

Probe: 20p11 (G) / BCL2L1 (R)



Process Description: WiCell works with client to determine their specific analysis requirements. This number connects those requirements to this final report and can be used for multiple samples or assays.

Interpretation:

There is evidence of duplication of the BCL2L1 gene. Forty-five of two hundred (22.5%) interphase cells examined show two probe signals for the 20p11.21 and three probe signals for the 20q11.21 (BCL2L1) regions.

The Empire Genomics red probe mapping to BCL2L1 at 20q11.21 and the Empire Genomics green probe mapping to the alpha satellite DNA at 20p11.21 (BCL2L1/CON20) were hybridized to this specimen, resulting in the signal patterns in interphase nuclei reported in the table and shown in the images above. The probes used for this assay were validated in this laboratory using guidelines established by the American College of Medical Genetics, NCCLS, and described in Wiktor et al., Genetics in Medicine 89(1),16-23 (2006) and Wolff et al., Journal of Molecular Diagnostics 9(2),134-143 (2007). The WiCell Cytogenetics Laboratory has established and verified the assay's performance.

Deviation: ***No deviations occurred.***

Description of any deviations, if applicable.

Completed by: ***Technologist Name***

The name of the technologist that drafted the report.

Director Review: _____

DocuSign signature of American Board of Medical Genetics and Genomics (ABMGG) board certified board-eligible director

Report Review: _____

DocuSign signature of certified technologist that reviewed the accuracy of the analysis, results, and report

QA Review: _____

DocuSign signature of QA member that reviewed the accuracy of the report

For internal use only

Date:_____ Sent By:____ Sent To:_____

Compliance statement

This assay was completed in compliance with the U.S. FDA Current Good Manufacturing Practice for Finished Pharmaceuticals (21 CFR part 211) and the EU Good Manufacturing Practice guidelines (EC EudraLex Volume 4) where applicable.

Limitations: This assay allows for microscopic visualization of numerical and structural chromosome abnormalities. The size of structural abnormality that can be detected is >3-10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is defined as the number of G-bands per haploid genome. It is documented here as "band level", i.e., the range of bands determined from the four karyograms in this assay. Detection of heterogeneity of clonal cell populations in this specimen (i.e.,mosaicism) is limited by the number of metaphase cells examined, documented here as "# of cells counted".

This assay was conducted solely for listed investigator/institution. Unless otherwise mutually agreed in writing, the services provided to you hereunder by WiCell Research Institute, Inc. ("WiCell") are governed solely by WiCell's Terms and Conditions of Service, found at www.wicell.org/privacyandterms. Any terms you may attach to a purchase order or other document that are inconsistent, add to, or conflict with WiCell's Terms and Conditions of Service are null and void and of no legal force or effect.